34 completed, 3 terminated, 2 unknown, 1 not yet recruiting. 41 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 41 | Completed 34, Terminated 3, Unknown 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 8 | Completed 6, Suspended 1, Terminated 1 |
Follow Schizoaffective Disorder: new trials by email Literature Review of Schizoaffective Disorder trials Research Report on Schizoaffective Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia Brexpiprazole, Cariprazine, [11C] PHNO - Schizoaffective Disorder, Schizophreniform Disorder | Phase 1 | Not yet recruiting | New York State Psychiatric Institute | 100 | 2026-12-01 | 2026-07-20 |
| Accelerated TMS in Psychosis repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Suspended | Beth Israel Deaconess Medical Center | 20 | 2022-11-29 | 2026-04-22 |
| Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia Minocycline - Schizophrenia, Schizoaffective Disorder | Phase 1 | Unknown | Pakistan Institute of Living and Learning | 60 | 2022-08-30 | 2022-04-29 |
| M1 Schizophrenia PET Study 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor, PET Scan - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Yale University | 18 | 2021-04-20 | 2024-11-12 |
| BXCL501 for Agitation in Schizophrenia Dexmedetomidine Hydrochloride, Placebos - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Yale University | 11 | 2020-03-09 | 2025-07-23 |
| The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia N-acetylcysteine (NAC), Placebo, Tryptophan - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Completed | University of Maryland, Baltimore | 88 | 2020-01-20 | 2026-02-11 |
| A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe - Schizo Affective Disorder, Schizophrenia | Phase 1 | Completed | Luye Pharma Group Ltd. | 48 | 2018-12-12 | 2019-08-13 |
| Clinical Trial of AVL-3288 in Schizophrenia Patients AVL-3288, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | New York State Psychiatric Institute | 24 | 2016-11-01 | 2019-01-22 |
| Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day) - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | H. Lundbeck A/S | 119 | 2016-09-01 | 2019-09-12 |
| A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder Aripiprazole Lauroxil - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Alkermes, Inc. | 47 | 2015-12-01 | 2016-07-14 |
| OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant Behavioral/Attitudinal OnTrack Role-Playing Game - Psychosis, Schizoaffective Disorder | Phase 1 | Completed | Center for Social Innovation, Massachusetts | 19 | 2015-06-01 | 2016-07-27 |
| Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Zogenix, Inc. | 60 | 2015-02-01 | 2022-10-31 |
| Bioavailability of LY03004 and Risperdal® Consta® LY03004, Risperdal® Consta® - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 108 | 2014-09-01 | 2015-03-04 |
| An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder Risperdal® Consta®, LY03004 - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 16 | 2014-07-01 | 2015-06-18 |
| RCT of Methotrexate Added to Treatment As Usual in Schizophrenia Methotrexate - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Pakistan Institute of Living and Learning | 92 | 2013-12-01 | 2015-09-22 |
| Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo - Borderline Personality Disorder, BPD | Phase 1 | Terminated | Maria de las Mercedes Perez Rodriguez | 92 | 2013-09-01 | 2022-10-10 |
| Effectiveness of Adherence Therapy for Schizophrenia Adherence therapy - Schizophrenia, Schizophreniform Disorder | Phase 1 / Phase 2 | Completed | The Hong Kong Polytechnic University | 134 | 2013-05-01 | 2016-02-19 |
| Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Rovi Pharmaceuticals Laboratories | 36 | 2013-04-01 | 2023-10-23 |
| Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder LY03004 - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 36 | 2013-03-01 | 2014-11-10 |
| Kuvan in People With Schizophrenia and Schizoaffective Disorder Kuvan, Multivitamin - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 27 | 2012-10-01 | 2017-09-13 |
Showing 20 of 41. Sign in to see all of them.
Psychotic Disorders (41) · Schizophrenia (40) · Mood Disorders (4) · Bipolar Disorder (3) · Depressive Disorder, Major (2) · Schizotypal Personality Disorder (2) · Autism Spectrum Disorder (1) · Borderline Personality Disorder (1) · Central Nervous System Diseases (1) · Depression (1) · Depressive Disorder (1) · Insulin Resistance (1) · Marijuana Abuse (1) · Mental Disorders (1) · Obesity (1)
Schizophrenia Spectrum and Other Psychotic Disorders (41) · Mental Disorders (40) · Bipolar and Related Disorders (3) · Mood Disorders (3) · Nervous System Diseases (3) · Behavior (2) · Chemically-Induced Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Personality Disorders (2) · Signs and Symptoms (2) · Behavioral Symptoms (1) · Body Weight (1) · Central Nervous System Diseases (1) · Child Development Disorders, Pervasive (1)
Paliperidone Palmitate (5) · 7-chloro-N-quinuclidin-3-yl-benzo(b)thiophene-2-carboxamide (1) · AVL3288 (1) · Acetylcysteine (1) · Amantadine (1) · Asian ginseng (1) · Ceftriaxone (1) · Dexmedetomidine (1) · Dronabinol (1) · Geritol (1) · Glycine (1) · Lu AF35700 (1) · Methotrexate (1) · Minocycline (1) · Modafinil (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · Luye Pharma Group Ltd. (4) · New York State Psychiatric Institute (3) · Pakistan Institute of Living and Learning (3) · Dartmouth-Hitchcock Medical Center (2) · North Suffolk Mental Health Association (2) · University of North Carolina, Chapel Hill (2) · Yale University (2) · Alkermes, Inc. (1) · Beth Israel Deaconess Medical Center (1) · Center for Social Innovation, Massachusetts (1) · Eli Lilly and Company (1) · FORUM Pharmaceuticals Inc (1) · H. Lundbeck A/S (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)
United States (28) · Pakistan (3) · Croatia (2) · Spain (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Hong Kong (1) · Mexico (1) · Puerto Rico (1) · Russia (1) · Slovakia (1) · South Africa (1)
A. Eden Evins, M.D., M.P.H. (1) · Alan I Green, MD (1) · Amy Sun, MD PhD (1) · Andrew Prescot, Ph.D. (1) · Brian A Fallon, MD (1) · Cort A Pedersen, MD (1) · David L Penn, PhD (1) · David Walling, PhD (1) · Dr.Inti Qurashi, MD (1) · Imran B Chaudhry, MD (1) · Jeffrey A Lieberman, M.D. (1) · Jeffrey A Lieberman, MD (1) · Jeffrey Olivet, MA (1)
PMID 38244179, PMID 20537128, PMID 20537130, PMID 24419307, PMID 24423017, PMID 25563714, PMID 26072311, PMID 26187603, PMID 26911397, PMID 27089154, PMID 36931838
K23DA018203 (1), R01DA013196 (1), R01DA026799 (1), R01MH093529 (1), R01MH113557 (1), R01MH139651 (1), R21DA030763 (1), R21MH123870 (1), U01MH094247 (1), UL1TR000067 (1)